!!Frank Grosveld - Curriculum vitae \\ __Education__ \\ *1965-1968: Chemistry, University of Amsterdam *1968-1972: Biochemistry, University of Amsterdam (Dutch equivalent M.Sc.) *1972-1976: Biochemistry, McGill University, Montreal, Canada. \\ __Professional experience__ \\ *1977 EMBO Fellow with Professor C. Weissmann, University of Zurich. *1978 Research Associate with Professor C. Weissmann. *1979 Research Associate with Dr. R. A. Flavell, University of Amsterdam. *1980 Royal Society Fellowship with Dr. R. A. Flavell at the National Institute for Medical Research, Mill Hill, London. *1981 MRC short-term appointment. National Institute for Medical Research, Mill Hill, London. *1982 Head of Division of Gene Structure and Expression, National Institute for Medical Research, Mill Hill, London. *1993 Appointment to Full Professor at the Dept. of Cell Biology at the Medical Faculty of the Erasmus University, Rotterdam, The Netherlands. \\ __Honours/prizes__ \\ *1986 Elected to membership of EMBO *1991 Jeantet Prize Medicine *1991 Elected Fellow of the Royal Society *1992 Howard Hughes International Research Scholar Award *1994 Elected member of the Dutch Royal Academy of Sciences *1994 Elected member of the New York Academy of Sciences *1995 Spinoza prize NWO, The Netherlands *2008 KNAW Professorship (Dutch Royal Academy of Sciences) \\ __Editorial boards __ \\ *1996-present Editorial board member of Genes to Cells *1997 Senior editor Genes & Function *1998-present Editorial board member of Molecular Cell *1999-present Editorial board member of Gene Therapy and Regulation *1999-2005 Editorial board member of The European Haematology Journal *2000-present Editorial board member of EMBO *2001-present Editorial board member of EMBO Reports *2008-present Epigenetics and Chromatin, co-editor-in-chief \\ __Commercial biotech activities __ \\ *1993 Cofounder of Therexsys, now Cobra Therapeutics (UK) *1998 Cofounder of 3Ophus (Rotterdam) *1999 Cofounder of Minos (Greece and Rotterdam) *2003 Setting up Harbour Antibodies (Rotterdam) *2004 Setting up Minos Protein Products (Rotterdam) *2004 Setting up Minos Genomics (Rotterdam) \\ __10 key publications__ \\ Grosveld, F., Blom van Assendelft, G., Greaves, D. and Kollias, G. Position-independent high level expression of the human ß-globin gene in transgenic mice. Cell, 51, 975-985, 1987. Greaves, D. R., Fraser, P., Vidal, M. A., Hedges, M. J., Ropers, D., Luzzatto, L. and Grosveld, F. A transgenic mouse model of sickle cell disorder. Nature, 343, 183-185, 1990. Hanscombe, O., Whyatt, D., Fraser, P., Yannoutsos, N., Greaves, D., Dillon, N. & Grosveld, F. Importance of globin gene order for correct developmental expression. Genes & Devel., 5, 1387-1394, 1991 Wijgerde, M.G.J.M., Grosveld, F.G. and Fraser, P.J. Transcription complex stability and chromatin dynamics in vivo. Nature, vol. 377: 209-213, 1995. Whyatt, D., Lindeboom, F., Karis, A., Milot, E., Hendriks, R., de Bruijn, M., Langeveld, A., Gribnau, J., Grosveld, F. and Philipsen, S. An intrinsic but cell nonautonomous defect in GATA-1 overexpressing mouse erythroid cells. Nature, 406:519-524, 2000. Tolhuis, B., Palstra, R.J., Splinter, E., Grosveld, F. and De Laat, W. Looping and interaction between hypersensitive sites in the active ß-globin locus. Molecular Cell, 10:1-20, 2002. Patrinos, G., de Krom, M., de Boer, E., Langeveld, A., Imam, A., Strouboulis, J., de Laat W. and Grosveld, F. Multiple interactions between regulatory regions are required to stabilise an Active Chromatin Hub. Genes & Dev. 18(12):1495-509, 2004. Rodriguez P, Bonte E, Krijgsveld J, Kolodziej KE, Guyot B, Heck AJ, Vyas P, de Boer E, Grosveld F, Strouboulis J. GATA-1 forms distinct activating and repressive complexes in erythroid cells. EMBO J. 2005;24:2354-66. Natalia Meier, Sanja Krpic, Patrick Rodriguez, John Strouboulis, Maria Monti, Jeroen Krijgsveld, Martin Gering, Roger Patient , Arnd Hostert, Frank Grosveld. Novel binding partners of Ldb1 are required for haematopoietic development, Development. 2006;133:4913-23. Monkhorst K, Jonkers I, Rentmeester E, Grosveld F, Gribnau J. X inactivation counting and choice is a stochastic process: evidence for involvement of an X-linked activator. Cell. 2008;132:410-21.